No near-term catalyst from this filing — the next major data readout (Phase 2b high-dose ribupatide) is not expected until mid-2027. Monitor for KAI-4729 Phase 1 initiation by year-end 2026 and any partner data from Hengrui at EASD (Sep 28-Oct 2). The $1.17B cash position removes near-term financing risk.
Price Chart
Executive Summary
Kailera Therapeutics reported Q2 2026 financial results, highlighting a net loss of $111.3M, a cash position of $1.17B to fund operations into mid-2028, and key pipeline progress including the active IND for ribupatide oral and full enrollment of the Phase 2b high-dose trial. As a pre-revenue clinical-stage biotech, the filing is neutral as it contains no revenue or earnings surprise to trade on, and the milestones are on track but data-readouts remain 12+ months away.
Key Facts
- Cash, cash equivalents and marketable securities of $1,171.8M as of June 30, 2026, expected to fund operations into mid-2028.
- Net loss of $111.3M for Q2 2026, compared to $28.9M in Q2 2025.
- R&D expenses were $101.1M for Q2 2026, up from $19.5M in Q2 2025.
- IND for ribupatide oral active with U.S. FDA; global Phase 3 obesity trials planned for first half of 2027.
- Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled (264 participants); data anticipated in mid-2027.
- Appointed Nur Nicholson as Chief Technology Officer and Kathleen Tregoning as Chief Corporate Affairs Officer.
- Added to the Russell 2000 Index effective June 29, 2026.
Financial Impact
Net loss widened to $111.3M from $28.9M YoY; cash burn increased as R&D spending rose $81.5M to $101.1M. Cash runway into mid-2028 is unchanged from prior guidance.
Risk Factors
- No revenue or approved products — pre-revenue clinical-stage company with widening losses.
- Key pipeline catalysts (Phase 2b, Phase 3 data) are 12-18 months away; stock may drift without near-term news.
- Competitive obesity market with established players (Novo Nordisk, Eli Lilly) and many other clinical-stage entrants.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-346919 |
| Document: ck0002096997-20260812.htm | 0001193125-26-346919 |
| Document: 0001193125-26-346919-index-headers.html | 0001193125-26-346919 |
| Document: 0001193125-26-346919-index.html | 0001193125-26-346919 |
| Document: 0001193125-26-346919.txt | 0001193125-26-346919 |
| 8-K Data (Synthetic) | 0001193125-26-346919 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | 3 | $14.91 $12.92 | ▼ −13.35% | ▼ −12.85% | $10.39 (−30.32%) |
Aug 12, 2026 7w ago | 8-K | $17.97 $17.47 | ▼ −2.78% | ▼ −0.82% | $10.39 (−42.18%) |
Jul 31, 2026 9w ago | Court Ruling | $16.94 $18.66 | ▲ +10.15% | ▲ +6.64% | $10.39 (−38.67%) |
Jul 24, 2026 10w ago | Court Ruling | $17.69 $17.05 | ▼ −3.62% | ▼ −3.99% | $10.39 (−41.27%) |
Jun 5, 2026 16w ago | Press Release | $19.70 $19.67 | ▼ −0.15% | ▼ −2.26% | $10.39 (−47.26%) |
May 26, 2026 18w ago | 8-K | $21.91 $22.38 | ▲ +2.15% | ▲ +1.68% | $10.39 (−52.58%) |
May 26, 2026 18w ago | Press Release | $21.91 $22.59 | ▲ +3.10% | ▲ +1.90% | $10.39 (−52.58%) |
May 13, 2026 20w ago | Press Release | $21.11 $19.62 | ▼ −7.06% | ▼ −5.90% | $10.39 (−50.78%) |
Apr 20, 2026 23w ago | 8-K | $25.22 $23.82 | ▼ −5.55% | ▼ −6.63% | $10.39 (−58.80%) |
Apr 20, 2026 23w ago | Insider Cluster | $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $10.39 (−57.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access